Blinatumomab (Blincyto®): A Comprehensive Monograph on the First-in-Class BiTE® Therapy for Acute Lymphoblastic Leukemia

[Executive Summary]

[Blinatumomab, marketed as Blincyto®, is a first-in-class immuno-oncology agent that has fundamentally altered the treatment landscape for B-cell precursor Acute Lymphoblastic Leukemia (B-ALL). As a Bispecific T-cell Engager (BiTE®) antibody construct, its novel mechanism of action involves physically linking a patient's endogenous T-cells to malignant B-cells, thereby directing the immune system to eradicate the cancer. This process is highly specific, targeting the CD19 antigen on B-cells and the CD3 complex on T-cells, and its efficacy is independent of traditional antigen presentation pathways, allowing it to overcome common tumor immune evasion mechanisms.]

[Pivotal clinical trials have unequivocally demonstrated its superiority over standard chemotherapy in multiple clinical settings. Initially proven in heavily pre-treated patients with relapsed or refractory (R/R) B-ALL, where it nearly doubled median overall survival, blinatumomab's clinical development has followed a strategic progression into earlier lines of therapy. It established a new therapeutic paradigm by proving effective in eradicating minimal residual disease (MRD), the strongest predictor of relapse, and converting a high percentage of patients to a deep, molecularly negative state that correlates with long-term survival. Most recently, landmark trials have established its role as a standard of care when added to frontline consolidation chemotherapy for both adult and pediatric patients, significantly improving survival rates and redefining the goals of initial therapy.]

[The safety profile of blinatumomab is distinct from cytotoxic chemotherapy and is characterized by on-target toxicities related to its potent immune-activating mechanism. The most significant of these are Cytokine Release Syndrome (CRS) and neurological toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which are addressed in a U.S. Food and Drug Administration (FDA) Boxed Warning. Management of these events requires specialized care, including initial hospitalization and a step-dosing strategy. Despite its high acquisition cost, multiple health economic analyses have concluded that blinatumomab is a cost-effective intervention due to the substantial survival and quality-of-life benefits it provides. This report provides a comprehensive analysis of blinatumomab, detailing its pharmacology, clinical efficacy, safety, regulatory history, and its comparative position within the evolving armamentarium of advanced therapies for B-ALL.]

[I. Introduction and Drug Profile]

Blinatumomab represents a paradigm shift in the treatment of B-cell precursor Acute Lymphoblastic Leukemia (B-ALL), moving beyond the non-specific cytotoxicity of conventional chemotherapy to a highly targeted approach that harnesses the power of the patient's own immune system.[1] It is the first globally approved Bispecific T-cell Engager (BiTE®) immuno-oncology therapy, a culmination of decades of research in antibody engineering and a cornerstone of modern immunotherapy.[1]

The drug is identified by its generic name, blinatumomab; its brand name, Blincyto®; and several developmental codes used during its research phase, including AMG103, MT103, and bscCD19xCD3.[5] It is classified as a biotech, monoclonal antibody-based therapeutic.[5] The development of blinatumomab was initiated by the German-American company Micromet, in collaboration with Lonza.[5] The transformative potential of the BiTE® platform was recognized by Amgen Inc., which acquired Micromet in 2012 and subsequently drove the large-scale clinical trials and global regulatory submissions that led to its widespread approval and commercialization.[5] Amgen remains the manufacturer and marketing authorization holder for Blincyto®.[3][ This acquisition trajectory is a characteristic example of how innovation from smaller biotechnology firms can be scaled and brought to patients globally through the resources and infrastructure of a large pharmaceutical organization.]

Blinatumomab is a recombinant protein therapeutic produced in a well-characterized mammalian cell line (Chinese Hamster Ovary, CHO) and purified through a multi-step process that includes viral inactivation and removal measures.[9] The construct consists of 504 amino acids and has an approximate molecular weight of 54 kilodaltons (kDa).[9][ This is consistent with its calculated molar mass of approximately 54,086.56 g·mol−1 and molecular formula of]

C2367​H3577​N649​O772​S19​.[5] The pharmaceutical product is supplied as a sterile, preservative-free, white to off-white powder in a single-use vial, which is co-packaged with a vial of IV solution stabilizer. Each vial contains 38.5 micrograms of blinatumomab. Upon reconstitution with sterile water for injection, the final solution has a blinatumomab concentration of 12.5 micrograms/mL. The formulation includes several excipients to ensure stability and compatibility for intravenous administration: citric acid monohydrate, trehalose dihydrate, lysine hydrochloride, polysorbate 80, and sodium hydroxide.[9]

Characteristic	Detail	Source(s)
Generic Name	Blinatumomab	5
Brand Name	Blincyto®	5
DrugBank ID	DB09052	5
CAS Number	853426-35-4	5
Type	Biotech, Bispecific Monoclonal Antibody	5
Drug Class	Antineoplastic Agent, Bi-specific T-cell Engager (BiTE®)	5
ATC Code	L01FX07 (WHO), L01XC19	5
Manufacturer	Amgen Inc.	8
Molecular Formula	C2367​H3577​N649​O772​S19​	5
Molecular Weight	~54 kDa (approx. 54,086 g·mol−1)	5
Source	Recombinant, Murine-derived variable fragments, produced in CHO cells	5

[II. Mechanism of Action: Engineering T-Cells to Eradicate Malignancy]

The therapeutic activity of blinatumomab is derived from its unique structure as a BiTE® antibody construct. Unlike a traditional monoclonal antibody with a 'Y' shape and two identical antigen-binding sites, blinatumomab is a single polypeptide chain engineered through recombinant DNA technology. It consists of two distinct single-chain variable fragments (scFv), one derived from an anti-CD19 antibody and the other from an anti-CD3 antibody, connected by a short, flexible, non-immunogenic peptide linker.[5] This streamlined design results in a relatively small molecule (~54 kDa) that can effectively penetrate tissues and connect two different cell types.[9]

[The dual specificity of the BiTE® construct is the cornerstone of its mechanism:]

1. CD19 Targeting: One scFv arm binds with high affinity to the CD19 antigen. CD19 is a transmembrane protein that is reliably expressed on the surface of cells throughout the B-lymphocyte lineage, from early B-cell precursors to mature B-cells. Crucially, it is also expressed on the vast majority of malignant lymphoblasts in B-ALL.[5] The expression of CD19 is largely restricted to B-cells, making it an ideal and specific target for directing therapy against B-cell malignancies while sparing most other tissues.[1]
2. CD3 Engagement: The second scFv arm binds to the CD3 epsilon (CD3E) subunit, a key component of the T-cell receptor (TCR) complex found on the surface of nearly all cytotoxic and helper T-cells.[5]

By simultaneously binding to a CD19-positive B-cell and a CD3-positive T-cell, blinatumomab functions as a molecular bridge, forcing the two cells into close physical proximity. This engineered interaction mediates the formation of a transient but highly potent cytolytic immunological synapse between the effector T-cell and the target cancer cell.[2]

The formation of this synapse triggers a cascade of events within the T-cell, leading to its powerful activation. This activation includes the upregulation of cell adhesion molecules, proliferation of the T-cell population, and the release of inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-α) and Interferon-gamma (IFN-γ).[7] Most importantly, it stimulates the T-cell to release cytotoxic proteins, primarily perforin and granzymes, into the synapse. These proteins perforate the membrane of the target B-cell and induce apoptosis, leading to its rapid and efficient destruction.[9]

A profound and strategically critical feature of this mechanism is that it is polyclonal and independent of the T-cell's native antigen specificity. The activation signal is delivered directly through the CD3 complex, bypassing the need for the T-cell's specific TCR to recognize a peptide antigen presented by a Major Histocompatibility Complex (MHC) molecule—also known as a Human Leukocyte Antigen (HLA) molecule—on the cancer cell's surface.[2][ This circumvents a primary mechanism of tumor immune evasion, wherein cancer cells downregulate their HLA expression to become "invisible" to the immune system. By redirecting any available T-cell to kill any CD19-positive cell, blinatumomab can function effectively even in patients whose tumors have developed this common resistance pathway.]

Furthermore, this mechanism provides a significant logistical advantage over personalized cell therapies. Blinatumomab is a standardized, "off-the-shelf" pharmaceutical product that can be administered immediately upon diagnosis or relapse.[9][ This contrasts sharply with autologous therapies like Chimeric Antigen Receptor (CAR) T-cells, which require a multi-week manufacturing process involving harvesting, genetically engineering, and expanding a patient's own T-cells. In an aggressive and rapidly progressing disease like B-ALL, this ability to initiate a potent immunotherapy without delay is of critical clinical importance.]

[III. Clinical Pharmacology: Pharmacokinetics and Pharmacodynamics]

[The clinical use and management of blinatumomab are directly informed by its distinct pharmacokinetic (PK) and pharmacodynamic (PD) properties.]

[Pharmacokinetics]

[The pharmacokinetic profile of blinatumomab has been characterized in both adult and pediatric patients with B-ALL.]

• Administration and Linearity: Blinatumomab is administered as a continuous intravenous (IV) infusion, which ensures 100% bioavailability.[5] Following the start of the infusion, serum concentrations rise to reach a steady state (Css) within approximately one day and remain stable thereafter.[9] The drug exhibits linear pharmacokinetics, meaning that increases in Css are approximately proportional to the administered dose over the clinically evaluated range of 5 to 90 micrograms/m²/day in adults.[9]
• Distribution: The estimated mean volume of distribution based on the terminal phase (Vz) is 4.52 L in adult patients, indicating that the drug's distribution is largely confined to the vascular and interstitial fluid compartments, consistent with a protein of its size.[9] Population pharmacokinetic analyses have shown that while body surface area is a covariate influencing PK parameters, demographic factors such as age (evaluated from 0.62 to 80 years) and gender do not have a clinically meaningful impact on the drug's disposition.[9]
• Metabolism and Elimination: As a protein-based therapeutic, blinatumomab is not metabolized by cytochrome P450 enzymes. Instead, it is presumed to be degraded into small peptides and amino acids through ubiquitous catabolic pathways, a process that has not been formally characterized.[5] The estimated mean systemic clearance is approximately 2.92 to 3.11 L/hour in adult patients.[7] Renal clearance is not a significant route of elimination, as negligible amounts of the drug are excreted in the urine.[5]
• Half-Life: A defining characteristic of blinatumomab is its very short elimination half-life, with a mean of 2.11 hours in adults and 2.19 hours in pediatric patients.[5][ This rapid clearance from the body is the primary pharmacological reason that continuous intravenous infusion is the required method of administration. A bolus dose would be eliminated too quickly to maintain the therapeutic concentrations necessary for sustained engagement between T-cells and B-cells. This pharmacokinetic property, while creating logistical challenges related to the infusion, also provides a crucial safety feature. In the event of severe, acute toxicities like CRS or neurotoxicity, stopping the infusion leads to rapid drug clearance and a comparatively swift resolution of the adverse event, a distinct advantage over therapies with long biological persistence.]

[Pharmacodynamics]

[The pharmacodynamic effects of blinatumomab are a direct and measurable manifestation of its mechanism of action, characterized by T-cell activation, B-cell depletion, and transient cytokine release.]

• T-Cell Activation and Redistribution: Following the start of the infusion, there is a characteristic biphasic effect on peripheral T-cell counts. An initial decline in T-cell numbers is observed within the first one to two days, which is attributed to the redistribution of T-cells from the circulation into tissues as they are activated and marginated. Subsequently, T-cell counts typically return to baseline or, in some cases, expand above baseline levels within one to two weeks, reflecting T-cell proliferation driven by the drug's activity.[9]
• Peripheral B-Cell Depletion: At therapeutically effective doses (≥5 micrograms/m²/day), blinatumomab induces rapid, profound, and sustained depletion of peripheral B-cells (both benign and malignant) to undetectable levels. This on-target effect serves as a clear pharmacodynamic marker of drug activity. The depletion is maintained throughout the treatment cycle, and no recovery of peripheral B-cell counts is observed during the two-week treatment-free interval between cycles.[7]
• Transient Cytokine Elevation: The activation of T-cells leads to a transient release of inflammatory cytokines into the circulation. The most prominently elevated cytokines are Interleukin-6 (IL-6), Interleukin-10 (IL-10), and Interferon-gamma (IFN-γ).[7] This cytokine spike is most pronounced within the first 24 to 48 hours after the initiation of the first infusion or following a dose escalation. The levels typically return to baseline within this 48-hour window even as the infusion continues. This response is attenuated in subsequent treatment cycles, with fewer patients experiencing cytokine elevation and with lesser intensity.[9][ This phenomenon is likely due to the significant reduction in tumor burden after the first cycle, resulting in a smaller pool of target cells to stimulate a massive T-cell response. The initial cytokine elevation is directly linked to the risk of CRS, making this early period of treatment a critical window for close patient monitoring.]

[IV. Clinical Efficacy in B-Cell Precursor Acute Lymphoblastic Leukemia]

[The clinical development of blinatumomab has been marked by a series of practice-changing trials that have progressively expanded its role from a last-resort salvage therapy to a standard of care in earlier treatment settings. This progression reflects its profound efficacy across the spectrum of B-ALL.]

[A. Pivotal Trial Analysis: Relapsed/Refractory (R/R) B-ALL (The TOWER Study)]

The TOWER study (NCT02013167) was the landmark, international, randomized, open-label Phase 3 trial that solidified blinatumomab's role in adult patients with Philadelphia chromosome-negative (Ph-) R/R B-ALL. This trial compared blinatumomab monotherapy to one of four pre-specified standard-of-care (SOC) chemotherapy regimens, representing the previous therapeutic standard for this difficult-to-treat population.[15] The results from TOWER were pivotal for converting the drug's initial accelerated FDA approval to a full approval.[17]

The study enrolled 405 patients, randomized 2:1 to receive either blinatumomab (n=271) or SOC chemotherapy (n=134).[16][ The primary endpoint was overall survival (OS). Blinatumomab demonstrated statistically significant and clinically meaningful superiority over SOC chemotherapy across all key efficacy endpoints.]

• Overall Survival: The median OS was nearly doubled in the blinatumomab arm, at 7.7 months, compared to 4.0 months in the SOC chemotherapy arm (Hazard Ratio 0.71; 95% Confidence Interval [CI], 0.55–0.93; p=0.012).[17] The survival benefit was even more pronounced in the prespecified subgroup of patients treated in their first salvage, where median OS was 11.1 months with blinatumomab versus 5.5 months with chemotherapy.[19]
• Remission Rates: Patients treated with blinatumomab achieved significantly higher rates of remission. The rate of complete remission with full, partial, or incomplete hematologic recovery (CR/CRh*/CRi) within 12 weeks of treatment initiation was 44% for blinatumomab versus 25% for SOC (p<0.001).[16]
• Depth and Duration of Remission: Blinatumomab not only induced more remissions but also deeper and more durable ones. Among patients who achieved remission, 76% in the blinatumomab arm became MRD-negative, compared to only 48% in the SOC arm.[19] The median duration of remission was also longer for the blinatumomab group (7.3 months vs. 4.6 months).[16]

Efficacy Outcome	Blinatumomab (n=271)	SOC Chemotherapy (n=134)	Statistic	Source(s)
Median Overall Survival (OS)	7.7 months	4.0 months	HR: 0.71; p=0.012	17
CR/CRh/CRi Rate*	44% (119/271)	25% (33/134)	p<0.001	16
MRD Negativity Rate (in responders)	76% (90/119)	48% (16/33)	-	19
Median Duration of Remission	7.3 months	4.6 months	-	16
Event-Free Survival at 6 Months	31%	12%	-	16

[B. Eradication of Minimal Residual Disease (MRD) (The BLAST Study)]

The presence of MRD following induction chemotherapy is the single most powerful prognostic factor for relapse in patients with ALL.[21][ The BLAST study (MT103-203; NCT01207388) was a Phase 2, single-arm trial designed specifically to assess blinatumomab's ability to eradicate this residual disease in adult patients with Ph-negative B-ALL who were in a complete hematologic remission but remained MRD-positive (defined as ≥]

10−3 leukemic cells).[21] The groundbreaking results of this study led to the first-ever FDA approval for an MRD-directed therapy in any cancer.[22]

The primary endpoint of the study was the rate of complete MRD response. After just one 4-week cycle of blinatumomab, 78% of evaluable patients (87/113) achieved a complete MRD response, meaning their disease became undetectable by highly sensitive molecular methods.[21] Long-term follow-up of the BLAST cohort, with a median of 59.8 months, demonstrated the profound impact of this deep remission on survival. For patients who achieved a complete MRD response, the median OS was not reached, whereas it was only 14.4 months for those who did not respond (p=0.002).[21] The estimated 5-year OS for complete MRD responders was 50%, a remarkable outcome for this high-risk population.[21] These results established that blinatumomab could effectively convert patients from a high-risk MRD-positive state to a low-risk MRD-negative state, serving as a critical bridge to potentially curative allogeneic hematopoietic stem cell transplantation (allo-HSCT) or, for some, enabling long-term survival without it.[21]

[C. Evolving Role in Frontline Therapy: The Consolidation Setting]

The remarkable success of blinatumomab in the R/R and MRD-positive settings prompted investigation into its use earlier in the treatment pathway. This strategy reflects a powerful trend in modern oncology: moving highly effective therapies into earlier lines of treatment to prevent relapse rather than treating it. The ECOG-ACRIN E1910 trial (NCT02003222) in adults and the Children’s Oncology Group (COG) AALL1731 trial (and its predecessor, 20120215) in pediatrics were designed to test this hypothesis by integrating blinatumomab into frontline consolidation chemotherapy.[26]

The results from these trials were practice-changing.[4] In the E1910 trial, adults with newly diagnosed Ph-negative B-ALL who received blinatumomab plus consolidation chemotherapy had a 5-year OS rate of 82.4%, compared to 62.5% for those who received chemotherapy alone (HR 0.44).[26] Strikingly, this survival benefit was observed even in patients who were already MRD-negative before receiving blinatumomab, suggesting the drug eliminates disease below the standard threshold of detection, thereby deepening remission and preventing relapse.[30]

Similarly, in pediatric patients with high-risk first relapse, the 20120215 study showed a 5-year OS of 78.4% with blinatumomab versus 41.4% with intensive chemotherapy (HR 0.35).[26] For standard-risk children, the AALL1731 trial showed that adding two cycles of blinatumomab to chemotherapy improved 3-year disease-free survival from 88% to 96%.[4]

These profound survival benefits led to the 2024 FDA and 2025 EMA approvals for blinatumomab for use in the consolidation phase of treatment for Ph-negative B-ALL, establishing it as a new standard of care in the frontline setting for both adult and pediatric patients.[8][ This clinical journey—from salvage to MRD eradication to frontline standard—demonstrates how a truly transformative therapy can progressively move earlier in the treatment algorithm to maximize patient benefit.]

[V. Safety and Tolerability Profile: Management of On-Target Toxicities]

The safety profile of blinatumomab is fundamentally different from that of traditional cytotoxic chemotherapy. Its adverse events are primarily driven by its intended mechanism of action—potent T-cell activation—and are therefore considered "on-target" toxicities. The most significant and potentially life-threatening of these are Cytokine Release Syndrome (CRS) and neurological toxicities, which are highlighted in a Boxed Warning required by the U.S. FDA.[3]

[Boxed Warnings in Detail]

• Cytokine Release Syndrome (CRS): CRS is a systemic inflammatory response triggered by the rapid release of a large quantity of cytokines from activated immune cells, particularly T-cells.[3]
• Clinical Presentation: The symptoms of CRS can range from mild, flu-like symptoms such as fever, headache, nausea, and fatigue, to severe and life-threatening manifestations including hypotension, tachycardia, hypoxia, capillary leak syndrome, and disseminated intravascular coagulation.[24] The clinical presentation can overlap with infusion reactions.[35]
• Incidence and Onset: In clinical trials, CRS was reported in approximately 15% of patients with R/R ALL and 7% of patients with MRD-positive ALL.[20] The onset is typically early, with a median time of 2 days after the start of the infusion. Among cases that resolved, the median time to resolution was 5 days.[20]
• Management: Management is guided by the severity of the reaction. It requires close monitoring of vital signs and symptoms. For severe (Grade 3) CRS, the blinatumomab infusion should be interrupted until the event resolves. For life-threatening (Grade 4) CRS, the drug must be permanently discontinued. Corticosteroids are the primary treatment for managing severe CRS.[9]
• Neurological Toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS):[ Neurological events are common and represent a significant risk of blinatumomab therapy.]
• Clinical Presentation: Patients can experience a wide spectrum of neurological signs and symptoms, including headache, tremor, dizziness, confusion, disorientation, aphasia (difficulty with speech), encephalopathy, disturbances in consciousness, loss of balance, and seizures.[33]
• Incidence and Onset: Neurological toxicities of any grade occurred in approximately 50-65% of patients in clinical trials, with severe (Grade ≥3) events occurring in about 13-15% of patients.[20] The median time to the first neurological event is within the first two weeks of treatment, often around day 7.[20]
• Management: Patients must be closely monitored for neurological changes. Management involves interrupting or permanently discontinuing the infusion based on the severity of the toxicity, and corticosteroids may be administered. Due to the risk of confusion and seizures, patients are advised not to drive or operate heavy machinery during treatment.[33] Patients with Down Syndrome may have a heightened risk of seizures and may receive prophylactic anti-seizure medication.[33]

[The fact that these severe toxicities are a direct result of the drug's powerful immune activation creates a delicate clinical challenge. The therapeutic goal is not to prevent the immune response but to modulate it, keeping the T-cell activation within a manageable range that is sufficient to kill cancer cells without causing uncontrollable systemic inflammation. This is achieved through strategies like step-dosing, premedication, and vigilant monitoring with prompt intervention.]

[Other Common and Serious Adverse Reactions]

[Beyond the boxed warnings, other important adverse events include:]

• Infections: Serious, life-threatening, or fatal infections were reported in approximately 25% of patients receiving blinatumomab.[24]
• Neutropenia and Febrile Neutropenia: Low white blood cell counts are common and can be severe, increasing the risk of infection. This was observed less frequently than with SOC chemotherapy but remains a significant event.[19]
• Tumor Lysis Syndrome (TLS): The rapid destruction of leukemia cells can lead to TLS, a potentially fatal metabolic complication. Preventive measures, including aggressive hydration and management of uric acid levels, are recommended.[24]
• Elevated Liver Enzymes and Pancreatitis: These have been reported and require laboratory monitoring.[33]

[Contraindications and Precautions]

• Contraindications: Blinatumomab is contraindicated in patients with a known history of hypersensitivity to the active substance or to any of the excipients in the formulation.[3] It is also contraindicated during breast-feeding.[38]
• [Precautions:]
• Vaccinations: Live virus vaccines should not be administered within 2 weeks before starting blinatumomab, during treatment, or until immune recovery after the final cycle.[33]
• Pregnancy and Reproduction: Blinatumomab may cause fetal harm. Females of reproductive potential should have a pregnancy test before starting treatment and must use effective contraception during treatment and for 48 hours after the last dose. Breastfeeding is not recommended during this same period.[33]

[VI. Dosage, Administration, and Patient Management]

[The administration of blinatumomab is a complex process dictated by its short pharmacokinetic half-life and its potent, acute safety profile. Adherence to the recommended protocols for dosing, infusion, and patient monitoring is critical for both efficacy and safety.]

[Method of Administration]

Blinatumomab is administered exclusively as a continuous intravenous (IV) infusion. This method is necessary to maintain the stable, steady-state drug concentrations required to keep T-cells continuously engaged with target B-cells.[5] The infusion is delivered at a constant flow rate using a programmable ambulatory infusion pump. The prepared infusion solution must be administered through IV tubing that contains a sterile, non-pyrogenic, low-protein-binding 0.2-micrometer in-line filter to ensure patient safety.[38]

[Dosing Regimens]

[The recommended dosage is intricate and varies based on the specific indication (e.g., R/R vs. MRD-positive), patient body weight, and the treatment cycle number.]

• Weight-Based Dosing: A key distinction is made for patients weighing 45 kg or more, who receive a fixed daily dose. Patients weighing less than 45 kg receive a dose calculated based on their body surface area (BSA), expressed as micrograms/m²/day, with a maximum dose cap to align with the fixed dose for heavier patients.[41]
• Step-Dose Strategy: For the initial treatment of R/R ALL, Cycle 1 employs a crucial step-dosing strategy to mitigate the risk of severe CRS. Patients begin with a lower starting dose (e.g., 9 mcg/day or 5 mcg/m²/day) for the first 7 days. If tolerated, the dose is then escalated to the target therapeutic dose (e.g., 28 mcg/day or 15 mcg/m²/day) for the remaining 21 days of the infusion.[41][ This gradual escalation allows the immune system to adapt to the T-cell activation, reducing the intensity of the initial cytokine surge.]

[Treatment Cycles]

[The treatment course is structured into distinct cycles, with the duration of the treatment-free interval varying by indication.]

• Induction and Consolidation Cycles: A standard cycle for these phases consists of 28 days (4 weeks) of continuous blinatumomab infusion, followed by a 14-day (2 weeks) treatment-free interval. The total duration of one such cycle is 42 days.[40]
• Continued Therapy Cycles: For patients with R/R ALL who achieve remission and proceed to continued therapy, the cycle structure is modified to consist of a 28-day infusion followed by a longer, 56-day (8 weeks) treatment-free interval, for a total cycle length of 84 days.[32]

[Patient Management and Logistical Considerations]

[The unique administration requirements and safety profile of blinatumomab necessitate a specialized approach to patient management.]

• Hospitalization: To ensure close monitoring for and rapid management of potential CRS and neurological toxicities, hospitalization is recommended for the initial days of treatment. For R/R ALL, this typically includes the first 9 days of Cycle 1 and the first 2 days of Cycle 2.[14] For all subsequent cycle starts or for re-initiation of an infusion after an interruption of 4 or more hours, supervision by a healthcare professional or hospitalization is recommended.[38]
• Premedication: To blunt the initial inflammatory response and reduce the risk of severe reactions, premedication is required. For adults, this typically involves an intravenous dose of a corticosteroid (e.g., 20 mg dexamethasone) administered one hour prior to the start of each cycle, before any dose escalation, and before restarting a paused infusion.[41] Pediatric protocols use weight-based dexamethasone doses.[41] Antipyretics like paracetamol are also recommended during the first 48 hours of each cycle to manage fever.[41]
• Outpatient and Home Infusion: After the initial inpatient monitoring period is completed without significant toxicity, the continuous infusion can be managed in the outpatient setting. This relies on a coordinated system involving the treatment center, specialty pharmacies, and either home health care providers or well-trained patient caregivers to manage the ambulatory infusion pump and change the infusion bags.[27] To facilitate this, the prepared blinatumomab solution can be supplied in infusion bags designed for 24, 48, 72, or 96 hours of infusion, providing flexibility for scheduling bag changes.[35]

The significant logistical burden associated with continuous IV infusion—requiring pumps, specialized training, and initial hospitalization—represents a major challenge for both patients and healthcare systems. This complexity has been the primary impetus for Amgen to pursue the development of a subcutaneous formulation of blinatumomab.[27][ A successful subcutaneous version, which could potentially be administered with simple injections, would dramatically reduce the treatment burden, improve patient quality of life, lower associated healthcare costs, and greatly expand the accessibility of this life-saving therapy.]

[VII. Regulatory and Developmental History]

[The regulatory journey of blinatumomab is a compelling narrative of a breakthrough therapy rapidly advancing through development and approval processes on both sides of the Atlantic, driven by strong clinical data in a disease with high unmet need. The timeline highlights a strategic progression from approvals in late-stage disease to its establishment as a standard of care in earlier treatment lines.]

The foundational BiTE® technology was developed by Micromet, which received an orphan drug designation for blinatumomab (then MT103) from the European Medicines Agency (EMA) for the treatment of ALL as early as 2009.[45] Following the acquisition of Micromet by Amgen in 2012, the clinical development program was accelerated.[5]

In the United States, the FDA recognized the drug's potential by granting it Breakthrough Therapy Designation in July 2014, followed by Priority Review designation in October 2014.[5] This paved the way for a rapid initial accelerated approval. The use of multiple expedited programs, including Real-Time Oncology Review (RTOR) and Project Orbis for later indications, underscores the consistent view of regulatory agencies that blinatumomab offers a major advance over available therapies.[26][ Project Orbis, an initiative for concurrent submission and review among international partners, particularly highlights the global consensus on the drug's importance and a modern approach to accelerating patient access.]

[The following table summarizes the key approval milestones and indication expansions by the FDA and EMA.]

Agency	Date	Action / Indication	Key Supporting Trial(s)	Source(s)
FDA	Dec 3, 2014	Accelerated Approval: R/R Ph- B-ALL (Adults & Children)	Phase 2 single-arm study	8
EMA	Nov 23, 2015	Conditional Authorisation: R/R Ph- B-ALL (Adults)	Study '211, Study '206	39
FDA	Jul 11, 2017	Full Approval: R/R B-ALL (Adults & Children), expanded to include Ph+	TOWER, ALCANTARA	8
EMA	Jun 18, 2018	Full Marketing Authorisation	TOWER	39
FDA	Mar 29, 2018	Accelerated Approval: MRD-positive B-ALL (Adults & Children)	BLAST	8
EMA	Aug 29, 2018	Expanded Indication: R/R Ph- B-ALL (Pediatric patients ≥1 year)	Study '205	48
FDA	Jun 21, 2023	Full Approval: MRD-positive B-ALL (Adults & Children)	AALL1331, Study 20120215	8
FDA	Jun 14, 2024	Full Approval: Frontline Consolidation for Ph- B-ALL (Adults & Children ≥1 month)	E1910, Study 20120215	8
EMA	Jan 29, 2025	Expanded Indication: Frontline Consolidation for Ph- B-ALL (Adults)	E1910	29

[VIII. Comparative Therapeutic Landscape]

[The advent of blinatumomab and other novel immunotherapies has created a complex but promising therapeutic landscape for B-ALL, offering alternatives to traditional chemotherapy. The optimal choice and sequencing of these agents is a central clinical question, guided by their distinct mechanisms, efficacy profiles, and toxicities.]

[A. Blinatumomab vs. Standard Chemotherapy]

[The comparison to standard-of-care (SOC) chemotherapy is the most well-defined. Across multiple randomized trials in different settings, blinatumomab has demonstrated clear superiority.]

• Efficacy: In the R/R setting (TOWER trial), blinatumomab nearly doubled median overall survival and produced significantly higher rates of deep, molecular remission compared to SOC chemotherapy.[16] In the frontline consolidation setting (E1910 trial), adding blinatumomab to chemotherapy dramatically improved 5-year overall survival from 62.5% to 82.4%.[26]
• Safety: While blinatumomab introduces the unique risks of CRS and neurotoxicity, it is associated with significantly lower rates of the hallmark toxicities of intensive chemotherapy, particularly severe myelosuppression (neutropenia) and infections.[17]
• Quality of Life: This difference in toxicity profile translates to patient-reported outcomes. In the TOWER study, patients treated with blinatumomab reported a better health-related quality of life (HRQL) across most domains compared to those receiving chemotherapy.[16]

[B. Blinatumomab vs. Inotuzumab Ozogamicin (InO)]

Inotuzumab ozogamicin is another targeted therapy for B-ALL, but it operates via a different mechanism. It is an antibody-drug conjugate (ADC) that targets the CD22 antigen on B-cells, delivering a potent cytotoxic payload (calicheamicin) directly into the cancer cell.[50]

• Efficacy: There are no head-to-head randomized trials comparing blinatumomab and InO. Indirect, matching-adjusted comparisons using data from their respective pivotal trials (TOWER for blinatumomab, INO-VATE-ALL for InO) suggest broadly similar overall efficacy in terms of OS and CR rates, though some analyses show minor differences in short-term survival or remission depth.[50]
• Toxicity and Patient Selection: The choice between these two agents in the clinic is often driven by their distinct and non-overlapping toxicity profiles. The primary concern with blinatumomab is CRS and neurotoxicity. The dose-limiting toxicity for InO is hepatotoxicity, specifically sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), which is a particularly high risk for patients who will subsequently undergo allo-HSCT.[51][ Therefore, clinical decision-making is often personalized:]
• Blinatumomab may be preferred for patients who are at high risk for VOD, such as those who have had a prior transplant or have underlying liver issues.[54]
• Inotuzumab ozogamicin may be preferred for patients with a very high tumor burden where rapid cytoreduction is paramount, or for those with active central nervous system (CNS) leukemia, as blinatumomab has limited experience in this setting.[54]

[C. Blinatumomab vs. CD19 CAR-T Therapy]

[CD19-directed CAR-T cell therapy is another powerful immunotherapy for B-ALL. While both therapies target the same CD19 antigen, their fundamental nature and logistics are vastly different.]

• Mechanism and Logistics: Blinatumomab is an "off-the-shelf" drug that engages a patient's existing, un-modified T-cells.[9] CAR-T therapy is a personalized, "living drug" that involves collecting a patient's T-cells (leukapheresis), genetically engineering them ex vivo to express a chimeric antigen receptor that recognizes CD19, expanding them to large numbers, and then infusing them back into the patient.[55][ This process is complex, costly, and takes several weeks.]
• Efficacy and Sequencing: Both therapies can induce high rates of deep, durable remissions. A critical and still-evolving area of research is the optimal sequencing of these agents. Emerging data from retrospective studies suggests that prior exposure to blinatumomab, particularly in patients who do not respond, may be associated with inferior outcomes following subsequent CD19 CAR-T therapy.[56] This may be due to mechanisms like CD19 antigen loss or modulation on the leukemia cells, which can render them resistant to further CD19-targeted treatment. This makes the initial choice of therapy a crucial strategic decision. Conversely, blinatumomab has shown some efficacy as a salvage option for patients who relapse after CAR-T therapy.[55]

Therapeutic Modality	Blinatumomab (Blincyto®)	Inotuzumab Ozogamicin (Besponsa®)	CD19 CAR-T Therapy (e.g., Tisagenlecleucel)
Mechanism of Action	Bispecific T-cell Engager (BiTE®)	Antibody-Drug Conjugate (ADC)	Genetically Engineered T-Cell
Target Antigen	CD19 (on B-cell) & CD3 (on T-cell)	CD22 (on B-cell)	CD19 (on B-cell)
Effector Component	Patient's endogenous T-cells	Calicheamicin (cytotoxin)	Patient's engineered T-cells
Logistics	Off-the-shelf; continuous IV infusion	Off-the-shelf; short IV infusion	Personalized; multi-week cell manufacturing
Signature Toxicity	Cytokine Release Syndrome (CRS), Neurological Toxicity (ICANS)	Hepatotoxicity, Veno-occlusive Disease (VOD)	Severe CRS, Severe ICANS, B-cell aplasia
Potential Clinical Niche	Patients at high risk for VOD; MRD eradication	High tumor burden; active CNS disease	Salvage after other failures; high-risk relapse

[IX. Economic Considerations and Health-Related Quality of Life (HRQL)]

[The introduction of highly effective but costly therapies like blinatumomab has necessitated a rigorous evaluation of their economic impact and value proposition from the perspective of patients, providers, and healthcare systems.]

[Cost and Cost-Effectiveness]

Blinatumomab carries a high acquisition cost. An early analysis by Memorial Sloan-Kettering Cancer Center, using a "value-based pricing" model, calculated a theoretical price of $12,612 per month, which stood in contrast to the reported market price at the time of $64,260 per month.[5]

[Despite its high price, multiple formal cost-effectiveness analyses have concluded that blinatumomab provides good value for money compared to previous standards of care, primarily because of the substantial survival benefits it confers.]

• vs. SOC Chemotherapy: A partitioned survival model based on the TOWER trial data estimated that, from a U.S. healthcare payer perspective, blinatumomab yields an additional 1.92 life years and 1.64 quality-adjusted life years (QALYs) compared to SOC chemotherapy, at an incremental cost of $180,642. This resulted in an incremental cost-effectiveness ratio (ICER) of $110,108 per QALY gained.[57] In the MRD-positive setting, an analysis based on the BLAST trial estimated an ICER of $81,807 per QALY gained.[59] Both of these values fall below the commonly accepted willingness-to-pay threshold of $150,000 per QALY in the U.S., leading to the conclusion that blinatumomab is a cost-effective treatment option.[57] Similar analyses in pediatric populations have reached the same conclusion, with one study in Canada reporting an ICER of approximately $21,970 CAD per QALY gained.[60]
• vs. Other Novel Agents: Economic comparisons with other novel agents are more complex. A real-world study suggested that treatment with inotuzumab ozogamicin was associated with lower total ALL-related healthcare costs than blinatumomab, a difference driven largely by shorter and less frequent hospitalizations.[50] An analysis comparing blinatumomab to the CAR-T therapy tisagenlecleucel found that while CAR-T was more effective, it was also substantially more expensive, yielding an ICER of $77,573 for CAR-T over blinatumomab.[61][ These analyses demonstrate that the value of blinatumomab is derived not from being an inexpensive option, but from being effective enough that its survival gains justify its cost within established healthcare economic frameworks.]

[Health-Related Quality of Life (HRQL)]

Beyond survival, the impact of treatment on a patient's quality of life is a critical outcome. A secondary objective of the TOWER study was to formally assess HRQL using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).[37]

The results showed a clear benefit for blinatumomab over SOC chemotherapy. In general, patients receiving blinatumomab reported better post-treatment HRQL across all functional and global health status scales.[37] Analyses of the time to a clinically meaningful deterioration in HRQL consistently favored blinatumomab. The hazard ratios for time to deterioration ranged from 0.42 to 0.81 in favor of blinatumomab across all subscales, with the only exceptions being insomnia, social functioning, and financial difficulties.[37][ This superior HRQL profile, coupled with the survival benefit, reinforces the overall clinical value of blinatumomab compared to the more debilitating effects of intensive salvage chemotherapy.]

[X. Conclusion and Future Directions]

Blinatumomab (Blincyto®) has unequivocally transformed the treatment of B-cell precursor Acute Lymphoblastic Leukemia. As the first-in-class BiTE® therapy, it has validated a novel immunotherapeutic strategy and established a new standard of care across the full spectrum of the disease. By demonstrating superior overall survival compared to chemotherapy in the relapsed/refractory setting, pioneering the concept of treating minimal residual disease to prevent relapse, and most recently, improving cure rates as part of frontline consolidation therapy, blinatumomab's clinical development has been a model of strategic innovation.[4][ Its unique mechanism, which bypasses conventional immune recognition pathways, and its manageable, albeit serious, on-target toxicity profile have made it a cornerstone of therapy for both adult and pediatric patients.]

[The journey of blinatumomab is, however, far from over. The future of this therapy is focused on addressing its current limitations and expanding its utility.]

• Subcutaneous Formulation: The most significant near-term evolution is the clinical development of a subcutaneous formulation.[27][ The current requirement for prolonged, continuous intravenous infusion is a major logistical and quality-of-life burden for patients. A subcutaneous version, if proven to be safe and effective, would represent a monumental step forward, simplifying administration, reducing healthcare resource utilization, and dramatically improving the patient experience.]
• Novel Combination Strategies: As blinatumomab becomes entrenched in frontline care, research is shifting towards optimizing its use in combination regimens. Ongoing and future trials are exploring its integration with other targeted agents, such as tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome-positive ALL, and other novel immunotherapies to create chemotherapy-free or chemotherapy-sparing regimens that could further improve efficacy while reducing toxicity.[58]
• Optimizing Therapeutic Sequencing:[ In the R/R setting, the availability of multiple powerful immunotherapies—blinatumomab, inotuzumab ozogamicin, and CAR-T cells—has created a new challenge: determining the optimal sequence of administration. Future clinical research will be critical to define which patients benefit most from which agent first, and how to manage resistance mechanisms like antigen loss to allow for effective sequential therapy.]

[In conclusion, blinatumomab is a landmark achievement in hematologic oncology. Its success has not only provided a lifeline for thousands of patients with B-ALL but has also paved the way for the broader development of the BiTE® platform and other T-cell engaging therapies across a range of cancers. Its continued evolution promises to further refine the treatment of leukemia, pushing the field closer to the goal of curative therapy for all patients.]

Works cited

1. What is the mechanism of action of Blinatumomab? - Patsnap Synapse, accessed July 24, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-blinatumomab
2. Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults - PMC, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5003562/
3. Ten Years of BLINCYTO® (blinatumomab): Celebrating the History, Impact and Future, accessed July 24, 2025, https://www.amgen.com/stories/2024/12/ten-years-of-blincyto---celebrating-the-history-impact-and-future
4. BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) - Amgen, accessed July 24, 2025, https://www.amgen.com/newsroom/press-releases/2024/12/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-bcell-precursor-acute-lymphoblastic-leukemia-ball
5. Blinatumomab - Wikipedia, accessed July 24, 2025, https://en.wikipedia.org/wiki/Blinatumomab
6. Blinatumomab (Anatumomab) | Antineoplastic Agent - MedchemExpress.com, accessed July 24, 2025, https://www.medchemexpress.com/blinatumomab.html
7. Blinatumomab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 24, 2025, https://go.drugbank.com/drugs/DB09052
8. Blincyto (blinatumomab) FDA Approval History - Drugs.com, accessed July 24, 2025, https://www.drugs.com/history/blincyto.html
9. www.tga.gov.au, accessed July 24, 2025, https://www.tga.gov.au/sites/default/files/auspar-blinatumomab-180205-pi.docx
10. CAS 853426-35-4 blinatumomab - BOC Sciences, accessed July 24, 2025, https://www.bocsci.com/product/blinatumomab-cas-853426-35-4-7145.html
11. blinatumomab | CDA-AMC - Canada's Drug Agency, accessed July 24, 2025, https://www.cda-amc.ca/blinatumomab-0
12. Blinatumomab | CAS NO.:853426-35-4 - GlpBio, accessed July 24, 2025, https://www.glpbio.com/blinatumomab.html
13. Blinatumomab Result Summary | BioGRID, accessed July 24, 2025, https://thebiogrid.org/chemical/7813/blinatumomab.html
14. Blinatumomab (Blincyto) chemo for ALL - ChemoExperts, accessed July 24, 2025, https://www.chemoexperts.com/blinatumomab-blincyto.html
15. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/30947585/
16. A trial comparing blinatumomab with chemotherapy for acute ..., accessed July 24, 2025, https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-comparing-blinatumomab-chemotherapy-acute-lymphoblastic-leukaemia-tower
17. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia - PMC, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6291336/
18. Full FDA Approval for Blinatumomab for ALL - NCI, accessed July 24, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2017/blinatumomab-all-fda-full-approval
19. BLINCYTO® (blinatumomab) Clinical Data | TOWER Study in ..., accessed July 24, 2025, https://www.blincytohcp.com/clinical-data/adult-aya/tower-landmark-study
20. BLINCYTO® Tower Study - Mayo Clinic School of Continuous Professional Development, accessed July 24, 2025, https://ce.mayo.edu/sites/default/files/Blincyto%20Tower%20Study-%20Relapsed%20or%20Refractory%20ALL.pdf
21. Full article: Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia - Taylor & Francis Online, accessed July 24, 2025, https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1780583
22. FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children - Amgen's investor, accessed July 24, 2025, https://investors.amgen.com/news-releases/news-release-details/fda-approves-blincytor-blinatumomab-treat-minimal-residual/
23. FDA Gives Full Approval to Blinatumomab in MRD-Positive B-Cell ALL - CancerNetwork, accessed July 24, 2025, https://www.cancernetwork.com/view/fda-gives-full-approval-to-blinatumomab-in-mrd-positive-b-cell-all
24. Amgen Announces New Data From Phase 2 BLINCYTO ..., accessed July 24, 2025, https://www.amgen.com/newsroom/press-releases/2014/12/amgen-announces-new-data-from-phase-2-blincyto-blinatumomab-immunotherapy-study-in-patients-with-acute-lymphoblastic-leukemia-and-minimal-residual-disease
25. Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) | ClinicalTrials.gov, accessed July 24, 2025, https://www.clinicaltrials.gov/study/NCT01207388?term=Blinatumomab&viewType=Table&rank=9&tab=results
26. FDA approves blinatumomab as consolidation for CD19-positive ..., accessed July 24, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell
27. Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL, accessed July 24, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2025/childhood-leukemia-blincyto-first-treatment
28. Blitzing ALL with blinatumomab | Blood - American Society of Hematology, accessed July 24, 2025, https://ashpublications.org/blood/article/145/21/2400/537284/Blitzing-ALL-with-blinatumomab
29. EUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE CD19-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CONSOLIDATION PHASE - PR Newswire, accessed July 24, 2025, https://www.prnewswire.com/news-releases/european-commission-approves-blincyto-in-philadelphia-chromosome-negative-cd19-positive-b-cell-precursor-acute-lymphoblastic-leukemia-in-the-consolidation-phase-302363668.html
30. Blinatumomab Extends Life for People with ALL in Remission - NCI, accessed July 24, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2023/blincyto-leukemia-minimal-residual-disease
31. EMA Recommends Extension of Indications for Blinatumomab | ESMO, accessed July 24, 2025, https://www.esmo.org/oncology-news/ema-recommends-extension-of-indications-for-blinatumomab2
32. Reference ID: 4123274 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed July 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125557s008lbl.pdf
33. B-Cell Precursor ALL Treatment | BLINCYTO® (blinatumomab), accessed July 24, 2025, https://www.blincyto.com/
34. Patient Resources | BLINCYTO® (blinatumomab), accessed July 24, 2025, https://www.blincyto.com/consolidation/resources
35. BLINCYTO® (blinatumomab): CD19-Positive B-Cell Precursor ALL ..., accessed July 24, 2025, https://www.blincytohcp.com/
36. Medication Guide BLINCYTO® (blin sye toe) (blinatumomab) for injection What is the most important information I should know abo - Amgen, accessed July 24, 2025, https://www.pi.amgen.com/united_states/blincyto/blincyto_mg_hcp_english.pdf
37. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab - PMC - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6024638/
38. blincyto, INN-blinatumomab - European Commission, accessed July 24, 2025, https://ec.europa.eu/health/documents/community-register/2015/20151123133349/anx_133349_en.pdf
39. Blincyto | European Medicines Agency (EMA), accessed July 24, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto
40. Dosing Information | BLINCYTO® (blinatumomab), accessed July 24, 2025, https://www.blincyto.com/consolidation/dosing
41. Blincyto, INN-blinatumomab - EMA, accessed July 24, 2025, https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf
42. BLINCYTO® (blinatumomab) for injection - accessdata.fda.gov, accessed July 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125557s013lbl.pdf
43. B cell precursor Acute Lymphoblastic Leukemia Active Not Recruiting Phase 1 / 2 Trials for Blinatumomab (DB09052) - DrugBank, accessed July 24, 2025, https://go.drugbank.com/indications/DBCOND0023533/clinical_trials/DB09052?phase=1%2C2&status=active_not_recruiting
44. The advantage of early blinatumomab treatment over chemotherapy in ALL - YouTube, accessed July 24, 2025, https://www.youtube.com/watch?v=RUcTUyZBCMs
45. EU/3/09/650 - orphan designation for treatment of acute ... - EMA, accessed July 24, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-650
46. FDA Approval: Blinatumomab - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/26374073/
47. European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia, accessed July 24, 2025, https://investors.amgen.com/news-releases/news-release-details/european-commission-approves-amgens-blincytor-blinatumomab/
48. European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia - Amgen, accessed July 24, 2025, https://www.amgen.com/newsroom/press-releases/2018/08/european-commission-approves-blincyto-blinatumomab-for-use-in-pediatric-patients-with-philadelphia-chromosomenegative-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukemia
49. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/29739753/
50. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting - Becaris Publishing, accessed July 24, 2025, https://becarispublishing.com/doi/10.57264/cer-2023-0142
51. Blinatumomab or Inotuzumab Ozogamicin As Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis, accessed July 24, 2025, https://ashpublications.org/blood/article/140/Supplement%201/12798/489090/Blinatumomab-or-Inotuzumab-Ozogamicin-As-Bridge-to
52. Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/37760592/
53. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6824351/
54. Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALL, accessed July 24, 2025, https://www.youtube.com/watch?v=ltd-8owRzUQ
55. Full article: Blinatumomab as salvage therapy in patients with ..., accessed July 24, 2025, https://www.tandfonline.com/doi/full/10.1080/07853890.2023.2230888
56. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL - ASCO Publications, accessed July 24, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.21.01405
57. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/28631497/
58. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective | Request PDF - ResearchGate, accessed July 24, 2025, https://www.researchgate.net/publication/317700942_Cost-effectiveness_of_blinatumomab_versus_salvage_chemotherapy_in_relapsed_or_refractory_Philadelphia-chromosome-negative_B-precursor_acute_lymphoblastic_leukemia_from_a_US_payer_perspective
59. Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective | Blood, accessed July 24, 2025, https://ashpublications.org/blood/article/132/Supplement%201/4746/262310/Cost-Effectiveness-of-Blinatumomab-Versus-Standard
60. Blinatumomab Is Cost-Effective Compared to Standard Chemotherapy for Children with High Risk Relapses of Acute Lymphoblastic Leukemia - American Society of Hematology, accessed July 24, 2025, https://ashpublications.org/blood/article/138/Supplement%201/565/480156/Blinatumomab-Is-Cost-Effective-Compared-to
61. Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor A - Chapman University Digital Commons, accessed July 24, 2025, https://digitalcommons.chapman.edu/cgi/viewcontent.cgi?article=1018&context=pharmaceutical_sciences_theses
62. Blinatumomab Effective for Children with Relapsed Leukemia - NCI, accessed July 24, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2021/blinatumomab-relapsed-b-cell-leukemia-children-young-adults
63. Blinatumomab Recruiting Phase 3 Trials for B-cell Acute Lymphoblastic Leukemia Treatment | DrugBank Online, accessed July 24, 2025, https://go.drugbank.com/drugs/DB09052/clinical_trials?conditions=DBCOND0034372&phase=3&purpose=treatment&status=recruiting